Table 1.
Baseline characteristics of 18 patients treated with sevelamer-carbonate
| Age (years) | 52.0 ± 13.8 |
| Sex (male/female) | 7/11 |
| Diabetes type 1 or 2 (%) | 22 (n = 4) |
| Body mass index (kg/m2) | 27.4 (24.8–32.9) |
| Race (% Caucasian) | 72.2 |
| eGFR (mL/min/1.73 m2) | 43.5 ± 9.6 |
| PWV (m/s) | 9.2 ± 2.3 |
| KI score (0–12) | 1.5 (0.0–8.0) |
| FGF23 (U/L) | 167 (121–234) |
| PTH (pmol/L) | 7.2 (6.1–10.0) |
| 25 OH vitD3 (nmol/L) | 69.6 ± 30.6 |
| 1,25(OH) vitamin D (pmol/L) | 82.6 ± 21.2 |
| Phosphate (mmol/L) | 1.12 ± 0.18 |
| Calcium (mmol/L) | 2.30 ± 0.12 |
| Urinary PO4 excretion (mmol/24 h) | 25.4 (16.4–35.0) |
| Urinary Ca excretion (mmol/ 24 h) | 1.5 (0.9–2.2) |
| Fractional PO4 excretion (%) | 23.5 (14.4–36.4) |
| Proteinuria (g/24 h) | 0.34 (0.0–1.66) |
| Haemoglobin (mmol/L) | 8.1 (7.5–9.2) |
| Albumin (g/L) | 37.0 ± 3.9 |
| Cholesterol (mmol/L) | 4.8 ± 0.8 |
| Low-density lipoprotein cholesterol (mmol/L) | 2.48 ± 0.65 |
| MAP (mmHg) | 99.5 ± 11.8 |
| Smoking (yes/no) | 5/13 |
| Use angiotensin-converting enzyme or angiotensin receptor blocker (%) | 72.2 |
| Use cholecalciferol (%) | 27.8 |
| Use active vitamin D (%) | 33.3 |
Baseline values expressed as mean±SD or median (IQR).